JP2008532953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532953A5 JP2008532953A5 JP2008500047A JP2008500047A JP2008532953A5 JP 2008532953 A5 JP2008532953 A5 JP 2008532953A5 JP 2008500047 A JP2008500047 A JP 2008500047A JP 2008500047 A JP2008500047 A JP 2008500047A JP 2008532953 A5 JP2008532953 A5 JP 2008532953A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sirolimus
- max
- auc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 42
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 34
- 229960002930 sirolimus Drugs 0.000 claims description 34
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 8
- 229940099538 rapamune Drugs 0.000 claims 8
- 239000007962 solid dispersion Substances 0.000 claims 5
- 241000282472 Canis lupus familiaris Species 0.000 claims 4
- 238000002844 melting Methods 0.000 claims 4
- 230000008018 melting Effects 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- -1 NaCMC Chemical compound 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000011874 heated mixture Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500344 | 2005-03-08 | ||
| PCT/DK2006/000135 WO2006094507A1 (en) | 2005-03-08 | 2006-03-08 | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008532953A JP2008532953A (ja) | 2008-08-21 |
| JP2008532953A5 true JP2008532953A5 (enExample) | 2009-04-16 |
Family
ID=36577478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008500047A Withdrawn JP2008532953A (ja) | 2005-03-08 | 2006-03-08 | シロリムスおよび／またはその類縁物質を含む医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080275076A1 (enExample) |
| EP (1) | EP1858511A1 (enExample) |
| JP (1) | JP2008532953A (enExample) |
| CN (1) | CN101137365A (enExample) |
| AU (1) | AU2006222409A1 (enExample) |
| BR (1) | BRPI0608573A2 (enExample) |
| CA (1) | CA2599758A1 (enExample) |
| MX (1) | MX2007010860A (enExample) |
| NO (1) | NO20075058L (enExample) |
| WO (1) | WO2006094507A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
| EP1952807A1 (en) | 2007-01-24 | 2008-08-06 | LEK Pharmaceuticals D.D. | Sirolimus formulation |
| TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| EP2365802B1 (en) | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
| US10485792B2 (en) | 2009-08-26 | 2019-11-26 | Hadasit Medical Research Services & Development Limited | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| WO2011122523A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 放出制御医薬組成物 |
| TR201802207T4 (tr) * | 2010-03-29 | 2018-03-21 | Astellas Pharma Inc | Kontrollü Salımlı Farmasötik Bileşim. |
| US8632979B2 (en) * | 2010-11-22 | 2014-01-21 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith |
| CN102008437B (zh) * | 2010-11-23 | 2012-11-14 | 赵晨 | 一种雷帕霉素眼用微乳注射剂及其制备方法和应用 |
| CN102138903B (zh) * | 2011-03-17 | 2012-12-12 | 苏州特瑞药业有限公司 | 一种依维莫司固体口服药物组合物 |
| CN103501812A (zh) * | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US8912215B2 (en) | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
| JP6573550B2 (ja) * | 2012-07-12 | 2019-09-11 | アッヴィ・アイルランド・アンリミテッド・カンパニー | Ｈｃｖ阻害剤の結晶形 |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| US20160022648A1 (en) | 2013-03-13 | 2016-01-28 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for meibomian gland dysfunction |
| US20160022649A1 (en) * | 2013-03-15 | 2016-01-28 | The Board Of Regents Of The University Of Texas System | Use of inhibitors of mtor to improve vascular functions in apoe4 carriers |
| CA2910584A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| CN104248636A (zh) * | 2013-06-28 | 2014-12-31 | 上海星泰医药科技有限公司 | 一种西罗莫司制剂及其制备方法 |
| CN113768881A (zh) | 2013-10-08 | 2021-12-10 | 人工智能治疗公司 | 用于治疗淋巴管平滑肌瘤病的雷帕霉素 |
| WO2015069870A1 (en) * | 2013-11-07 | 2015-05-14 | The University Of North Carolina At Chapel Hill | Particles containing phospholipids or bioactive fatty acid |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| BR112016018365A2 (pt) | 2014-02-11 | 2017-08-08 | Lam Therapeutics Inc | Formulação farmacêutica aerossol, na forma de um pó seco para distribuição pulmonar, seus usos, forma de dosagem unitária, embalagem ou kit farmacêutico, e dispositivo de distribuição de pó seco |
| HUP1400075A2 (hu) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| CA2944075C (en) | 2014-04-04 | 2022-06-28 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for treating age-related conditions |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| WO2016057712A1 (en) * | 2014-10-07 | 2016-04-14 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| US10603325B2 (en) | 2014-10-29 | 2020-03-31 | University Of Maryland | Methods of treating age-related symptoms in mammals and compositions therefor |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| US20160374616A1 (en) * | 2015-06-24 | 2016-12-29 | Daqri, Llc | Electrode contact quality |
| JP6855470B2 (ja) * | 2016-05-27 | 2021-04-07 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US20190250208A1 (en) * | 2018-02-09 | 2019-08-15 | Qualcomm Incorporated | Apparatus and method for detecting damage to an integrated circuit |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| AU2020410545A1 (en) * | 2019-12-19 | 2022-08-11 | Triviumvet Dac | Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204243B1 (en) * | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
| IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
| BR0210867A (pt) * | 2001-07-06 | 2004-06-29 | Lifecycle Pharma As | Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio |
-
2006
- 2006-03-08 AU AU2006222409A patent/AU2006222409A1/en not_active Abandoned
- 2006-03-08 US US11/885,992 patent/US20080275076A1/en not_active Abandoned
- 2006-03-08 EP EP06706106A patent/EP1858511A1/en not_active Withdrawn
- 2006-03-08 WO PCT/DK2006/000135 patent/WO2006094507A1/en not_active Ceased
- 2006-03-08 CA CA002599758A patent/CA2599758A1/en not_active Abandoned
- 2006-03-08 BR BRPI0608573A patent/BRPI0608573A2/pt not_active IP Right Cessation
- 2006-03-08 JP JP2008500047A patent/JP2008532953A/ja not_active Withdrawn
- 2006-03-08 MX MX2007010860A patent/MX2007010860A/es not_active Application Discontinuation
- 2006-03-08 CN CNA2006800074780A patent/CN101137365A/zh active Pending
-
2007
- 2007-10-08 NO NO20075058A patent/NO20075058L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532953A5 (enExample) | ||
| US12403140B2 (en) | Pharmaceutical compositions of nilotinib | |
| KR101512404B1 (ko) | 디하이드로피리딘 칼슘 채널 길항제를 포함하는 향상된 의약 조성물 및 이의 준비 방법 | |
| US20050249799A1 (en) | Polymeric drug delivery system for hydrophobic drugs | |
| US12138255B2 (en) | Pharmaceutical compositions of cabozantinib | |
| TW201446286A (zh) | 抗病毒化合物之固態分散調製劑 | |
| WO2008064202A2 (en) | Modified-release formulations of calcium receptor-active compounds | |
| US20210260084A1 (en) | Pharmaceutical composition comprising dapagliflozin | |
| US20150064252A1 (en) | Solid dispersion formulation of an antiviral compound | |
| NZ576987A (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
| KR102363727B1 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
| KR101931489B1 (ko) | 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법 | |
| KR20220077094A (ko) | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 | |
| US20080167325A1 (en) | Valacyclovir compositions | |
| US20080182908A1 (en) | Pharmaceutical compositions comprising memantine | |
| EP3079672B1 (en) | Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline | |
| CA3053566A1 (en) | Solid oral formulations of amphotericin b | |
| US20210369615A1 (en) | Solid oral formulations of amphotericin b | |
| EP3156049A1 (en) | Pharmaceutical composition of prasugrel | |
| WO2023227997A1 (en) | Pharmaceutical composition containing combination of azilsartan and chlorthalidone and process of preparation thereof | |
| JP5321454B2 (ja) | 医薬錠剤の製造法 | |
| US20060141044A1 (en) | Pharmaceutical compositions based on diclofenac derivate | |
| US20150119317A1 (en) | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate | |
| MXPA00006574A (en) | Method and composition of an oral preparation of itraconazole |